Replies to post #452302 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I used to think that, but remember, they were thinking they’d start running practice tests at the same time they predicted getting final imp certification at Sawston Aka: predicted Sept 2021, but it did not happen until Christmas 2021 and first patient did not get treated until mid February 2021. So no, I don’t think you can say the second EDEN milestone occurred last summer. Not saying it didn’t, but it is not nearly as likely. Confirming the second milestone shouldn’t be hard, but they don’t care, because they now know the results, and they are not likely interested in what retail is interested in at this juncture.

[exwannabe]

So it was not a small feat to find a new supplier to produce a prototype of the EDEN cartridge within 90 days of the Flaskworks’ acquisition. This first milestone was likely accomplished on time in November of 2020, since 1.5M shares were paid out on December 1, 2020 in accordance with the first milestone. (see 10K below)

Yes, the first milestone was completed then. The numbers are very clear. With the 1.5M shares for each of the 4 milestones and 1.5M share issued.

On the other hand, there is no mention of another 1.5M shares being paid for the second milestone. That is a bright line.

The clause you bold is messy. Recognizing expenses is not the same as a milestone being achieved.

You assert the second milestone should be easy, all they need to do is replicate what they did in their labs. That is false. You are saying a generic DC manufacturing process is the same as NWBO's "secret sauce" process.

[Evaluate]

Patent Grant 11268058
U.S. patent number 11,268,058 [Application Number 17/074,893] was granted by the patent office on 2022-03-08 for systems and methods for cell culturing.

https://uspto.report/patent/grant/11,268,058